Abzena PLC (LON:ABZA)‘s stock had its “buy” rating reissued by investment analysts at FinnCap in a research report issued on Wednesday, May 24th. They presently have a GBX 80 ($1.01) target price on the stock. FinnCap’s price objective indicates a potential upside of 92.77% from the company’s previous close.

Several other brokerages also recently commented on ABZA. N+1 Singer reiterated a “corporate” rating on shares of Abzena PLC in a report on Tuesday, February 21st. Numis Securities Ltd reiterated a “buy” rating and issued a GBX 90 ($1.14) target price on shares of Abzena PLC in a report on Tuesday, February 21st.

Shares of Abzena PLC (LON:ABZA) traded down 3.49% on Wednesday, hitting GBX 41.50. 108,667 shares of the stock were exchanged. The stock’s market cap is GBX 56.85 million. The stock’s 50-day moving average is GBX 37.16 and its 200-day moving average is GBX 37.00. Abzena PLC has a 1-year low of GBX 31.00 and a 1-year high of GBX 66.00.

COPYRIGHT VIOLATION WARNING: “Abzena PLC (ABZA) Given Buy Rating at FinnCap” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/06/16/abzena-plcs-abza-buy-rating-reaffirmed-at-finncap-updated-updated.html.

About Abzena PLC

Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.

Receive News & Stock Ratings for Abzena PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena PLC and related stocks with our FREE daily email newsletter.